Breast Cancer Clinical Trial
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
Summary
Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer. Docetaxel is approved by the Food and Drug Administration (FDA) as a second line therapy for these cancers. The imexon is administered on days 1-5 and the docetaxel on day 1 of every 3 week cycle. The objective of the protocol is to determine the highest dose of imexon which can be given with a full dose of docetaxel, and to provide information to enable the design of a future study focused on one or more specific cancer types.
Eligibility Criteria
Inclusion Criteria:
Be diagnosed with previously treated breast, lung, or prostate cancer where docetaxel is indicated.
Prior treatment; at least one prior regimen required.
Able to perform the activities of daily living.
Off prior cancer therapy for at least 4 weeks.
If female neither pregnant nor nursing.
Willing to use contraceptives to prevent pregnancy.
No other serious illnesses.
No other active malignancy.
No serious infections.
No other current drug therapy for the cancer.
Blood counts and blood chemistries in or near normal range.
Prior radiation is permitted.
Exclusion Criteria:
Active brain metastases.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Houston Texas, 77030, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.